Publication date: Jan 22, 2025
To compare the impact of COVID-19 on the clinical status and psychological distress of patients with immune-mediated rheumatic disease (IMRD) caused by SARS-CoV-2 infection with that of noninfected IMRD controls during a 6-month follow-up period. The ReumaCoV Brazil is a longitudinal study designed to follow IMRD patients for 6 months after COVID-19 (patients) compared with IMRD patients without COVID-19 (controls). Clinical data, disease activity measurements and current treatments regarding IMRD and COVID-19 outcomes were evaluated in all patients. Disease activity was assessed through validated tools at inclusion and at 3 and 6 months post-COVID-19. Fatigue, using FACIT-F (Functional Assessment of Chronic Illness Therapy) and psychological distress, using DASS 21 (Depression, Anxiety and Stress Scale - 21 Items), used to evaluated psychological distress, were evaluated at 6 months after COVID-19 in both groups. The significance level was set as p
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | MESH | rheumatic disease |
| disease | MESH | psychological distress |
| pathway | REACTOME | Disease |
| disease | IDO | disease |
| pathway | REACTOME | SARS-CoV-2 Infection |
| disease | MESH | Chronic Illness |
| disease | MESH | Depression |
| disease | MESH | Anxiety |
| disease | MESH | Long Covid |
| disease | MESH | Arthritis Rheumatoid |
| disease | MESH | Lupus Erythematosus Systemic |
| disease | MESH | Stress Psychological |